Skip to main content
    I

    Intensity Therapeutics, Inc. Common stock (INTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.01 (-0.32%)

    Market Cap: $10.17M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Intensity Therapeutics, Inc. Common stock (INTS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Intensity Therapeutics, Inc. Common stock (INTS) to earn -$4.20 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy6100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$4.20
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$2.21
    EPS consensus

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$4.20-$4.25 to -$4.153
    Dec 31, 2027-$2.21-$3.06 to -$0.923

    Quarterly Estimates

    The EPS consensus rises from -$0.77 for the quarter ending Dec 31, 2026 to -$0.51 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.77-$1.09 to -$0.217
    Mar 31, 2027-$0.51-$0.81 to -$0.212

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202603
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.13.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$4.20-$3.36-$3.36-$3.36-$3.13N/A
    Fiscal year ending Dec 31, 2027-$2.21-$1.99-$1.99-$1.99-$2.70N/A
    Quarter ending Mar 31, 2027-$0.51-$0.51-$0.51-$0.51N/AN/A

    Frequently Asked Questions About INTS

    What is the INTS stock forecast?

    Consensus analyst estimates put Intensity Therapeutics, Inc. Common stock's EPS at -$4.20 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.

    How do analysts rate INTS stock?

    Of 6 analysts covering Intensity Therapeutics, Inc. Common stock, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from INTS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.20, with estimates from -$4.25 to -$4.15 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.21, with estimates from -$3.06 to -$0.92 from 3 analysts.

    How many analysts cover INTS?

    6 analysts rate Intensity Therapeutics, Inc. Common stock stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.